This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Arrhythmia Atrial Fibrillation Technology 
Science Daily - Heart Disease
APRIL 22, 2024
Atrial fibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. Researchers have recently developed a deep-learning model capable of predicting the transition from a normal cardiac rhythm to atrial fibrillation.
119 
DAIC
DECEMBER 29, 2023
Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent.
HeartRhythm
JULY 21, 2024
The global health challenge posed by cardiac arrhythmias, particularly atrial fibrillation (AF), is significant, with heightened risks of stroke, heart failure, and systemic embolism1.
45 
DAIC
JULY 16, 2024
mtaschetta-millane Tue, 07/16/2024 - 09:47 July 16, 2024 — Ultrahuman, a pioneer in wearable technology , launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. AFib is the most common type of irregular heart rhythm or arrhythmia.
105 
HeartRhythm
AUGUST 31, 2024
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Smart technologies such as smartphones and smartwatches used in everyday life offer promising avenues for enhancing AF management.
Cardiomatics
APRIL 5, 2024
In a world where technology reigns supreme, one of the most profound tools in medicine remains the irreplaceable electrocardiogram (ECG). As technology advances, so too does our ability to capture the heart’s rhythm with greater precision. AFIB/AFL – atrial fibrillation or atrial flutter episodes.
92 
MIBHS
JANUARY 31, 2025
In the age of technology, wearable devices have revolutionized how we approach health and wellness. This blog explores the ways wearable technology can help track heart health, the advantages it offers, and how it contributes to better outcomes for those requiring surgical intervention.
52 
Frontiers in Cardiovascular Medicine
DECEMBER 19, 2023
Background The rising adoption of wearable technology increases the potential to identify arrhythmias. Herein, we report results of a follow-up screening protocol for incident atrial fibrillation/flutter (AF) within a large observational digital health study. Mean age was 50.5 (SD years, and 46 (53.3%) were female.
HeartRhythm
SEPTEMBER 23, 2024
Atrial fibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
DAIC
FEBRUARY 2, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. AFib is the most common type of cardiac arrhythmia and affects more than 6 million people in the United States and nearly 38 million people worldwide.2,3 In: AF Symposium.;
105 
HeartRhythm
AUGUST 31, 2024
Patients with CLL are at increased risk of developing atrial fibrillation (AF), however AF is a known side effect of ibrutinib therapy as well and is associated with worse outcomes. The incidence of atrial fibrillation (AF) is 10-15% with a median time to occurrence of 5-13 months.
DAIC
FEBRUARY 27, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , announced the commencement of patient cases with the investigational Laminar Left Atrial Appendage Elimination (LAAX) System as part of its pivotal investigational device exemption (IDE) study.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) catheter ablation trials report arrhythmia-free survival using different post-ablation rhythm monitoring protocols, resulting in difficulties in the interpretation of the recurrence rates and comparison of ablation strategies and technologies.
DAIC
JUNE 11, 2024
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.
104 
Journal of Cardiovascular Electrophysiology
OCTOBER 3, 2024
Abstract Introduction Atrial fibrillation (Afib) is a prevalent chronic arrhythmia associated with severe complications, including stroke, heart failure, and increased mortality. Despite ethical considerations and disparities, the potential benefits outweigh the challenges.
HeartRhythm
APRIL 30, 2024
TARLess is a novel technology that enables LAT mapping in absence of any TAR offers promising step toward atrial fibrillation activation mapping.
40 
DAIC
MARCH 26, 2024
The most common arrhythmia, atrial fibrillation , will affect approximately 12.1 Food and Drug Administration (FDA) in July 2023, a new leadless pacemaker system placed in both chambers of the heart and using a novel communication technology is now offering a more minimally invasive option for patients.
105 
DAIC
JULY 30, 2024
The Heart Rhythm Society (HRS) is preparing for HRX 2024, the third annual event of its kind, which will be held from September 5-7, 2024, in Atlanta, GA, gathering cardiovascular health innovators together to explore discoveries and advance partnerships between medicine and technology.
105 
HeartRhythm
AUGUST 31, 2024
Wearable technologies are being used by patients for ECG rate and rhythm monitoring. To date, it has not been possible to incorporate the collected data into clinical practice.
HeartRhythm
APRIL 30, 2024
Introduction: Pulsed Field Ablation (PFA) technologies are being studied in a number of clinical trials, many with strict inclusion/exclusion criteria-typically younger patients with less comorbidities undergoing de-novo PVI procedures.
40 
DAIC
DECEMBER 26, 2023
a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
59 Journal of Cardiovascular Electrophysiology
JANUARY 10, 2024
Abstract Introduction Despite advanced ablation strategies and major technological improvements, treatment of persistent atrial fibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood. Most arrhythmia recurrences were reentrant AT. After a total of 1.46 ± 0.68
Journal of Cardiovascular Electrophysiology
MARCH 4, 2024
ECG data during the clinical arrhythmia (ventricular tachycardia [VT], upper left figure) is analyzed with an artificial intelligence algorithm which identifies a probable location of the source of the arrhythmia (left ventricular anterolateral papillary muscle, lower left figure). cm, LVEF 50 ± 18%) and was similar to 28 controls.
40 
HeartRhythm
MAY 15, 2024
In the past decade, major advances were made in catheter ablation for arrhythmias and implantation of cardiac implantable electronic devices.1 1 Catheter ablation for atrial fibrillation (AF) and ventricular tachycardia (VT) has become the standard of care for many patients presenting with these arrhythmias.2–4
Dr. S. Venkatesan MD
MAY 15, 2024
RAFT AF (Again equivocal) With emerging new technologies, scientists are trying whether more safer methods like cryoablation or pulse-filed ablation would beat the rate control with drugs. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials.”
52 
DAIC
MAY 17, 2024
milla1cf Fri, 05/17/2024 - 18:54 May 17, 2024 — Royal Philips , a global leader in health technology, is presenting new retrospective study results demonstrating the clinical and economic benefits of Philips’ AI-powered cardiac care solutions at the Heart Rhythm Annual Meeting in Boston (May 16-19).
52 
CineECG
MAY 22, 2023
Over the past 3 days cardiologists from all over the world met in New Orleans to learn and discuss the developments in technology and patient care. As ECG Excellence we are proud our CineECG technology was part of this innovation festival. Their study focuses on the issue of localizing the origin of atrial ectopic activity.
52 
Journal of Cardiovascular Electrophysiology
DECEMBER 7, 2023
Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Compared to PFA VHPSD-PVI might ensure information on left atrial substrate allowing to target concomitant secondary tachycardias.
40 
Cardiomatics
JANUARY 5, 2023
It is a cloud-based AI Holter ECG analysis technology which can analyze signals recorded in various data formats regardless of the length of the ECG recording. It was very challenging to manually validate our results, especially with patients with multiple AF (Atrial Fibrillation) episodes and noisy recordings.
DAIC
DECEMBER 19, 2023
OSA is commonly seen in patients with arrhythmias like atrial fibrillation (AFib) and due to the variable unpredictable nature of sleep apnea symptoms, it is often untreated, leading to adverse outcomes. FACC, FHRS, FHSC , Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David's Medical Center.
Cardiomatics
JANUARY 23, 2023
It also requires a lot of counting when a doctor wants to know what the share of arrhythmias in the signal is. What’s more, it’s a truly hardware-agnostic platform for arrhythmia diagnostics and is compatible with more than 25 common ECG recording devices ranging from modern Holter Patches to classic multi-lead Holters.
52 
CardiacWire
DECEMBER 3, 2023
Jimenez and Ali co-founded AccurKardia in 2019 with a vision for unlocking the value of the ECG signal, and the company currently markets one of the few FDA-cleared solutions for automated ECG interpretation and arrhythmia detection. Here’s the rest of their story and vision for ECG automation.
52 
DAIC
FEBRUARY 14, 2025
In particular, the study showed superiority in the percentage of patients that achieved freedom from atrial fibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. tim.hodson Fri, 02/14/2025 - 09:57 Feb.
DAIC
MARCH 31, 2025
tim.hodson Mon, 03/31/2025 - 15:02 March 31, 2025 iRhythm Technologies, Inc. arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden. arrhythmia yield versus 69.1% Drawing on data from more than 1.1
52 
DAIC
MAY 18, 2024
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
105 
DAIC
JULY 24, 2024
Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.
DAIC
FEBRUARY 7, 2024
milla1cf Wed, 02/07/2024 - 18:05 February 7, 2024 — The Consumer Technology Association ( CTA ) and the American College of Cardiology ( ACC ) are announcing the release of their second industry framework for the use of consumer cardiovascular technology solutions in the screening and diagnosis for cardiovascular conditions.
116 
DAIC
APRIL 9, 2024
An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
DAIC
FEBRUARY 12, 2024
milla1cf Mon, 02/12/2024 - 15:18 February 12, 2024 — BIOTRONIK , a leader in implantable medical device technology, announced today they will solely supply their proprietary DX models for new single-chamber ICD implants moving forward. For more information: [link] References: Thomas G, Choi DY, Doppalapudi H, et al. January CT, et al.
64 
MIBHS
FEBRUARY 28, 2025
Arrhythmias: Genetic mutations can also predispose individuals to irregular heart rhythms, such as atrial fibrillation or long QT syndrome, which may increase the risk of stroke or sudden cardiac arrest. Cardiomyopathies: These diseases affect the heart muscle, impairing its ability to pump blood effectively.
DAIC
FEBRUARY 2, 2024
milla1cf Fri, 02/02/2024 - 17:18 February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 with CardioLab EP Recording system, to help clinicians in the diagnosis and treatment of cardiac arrhythmias. million people in the United States by 2050 and 17.9 million in Europe by 2060.
Journal of Cardiovascular Electrophysiology
MARCH 19, 2025
ABSTRACT Introduction Pulmonary vein isolation (PVI) using a cryoballoon is well-established for the treatment of paroxysmal atrial fibrillation (PAF). Compared to other available technologies, the usage of a stable, low-pressure cryoballoon (POLARx, Boston Scientific) has demonstrated lower nadir temperatures and longer thawing times.
DAIC
MARCH 5, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). ii] ClinicalTrials.gov.
59 
DAIC
MAY 24, 2024
Researchers hypothesized that an AI program trained to analyze echocardiograms might help clinicians detect early, subtle changes in the hearts of patients with undiagnosed arrhythmias. “We Atrial fibrillation can come and go, so it might not be present at a doctor’s appointment. An estimated 12.1
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content